Sermorelin vs Tesamorelin
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Sermorelin is discussed in the provided sources as a growth hormone secretagogue/growth hormone releasing hormone (GHRH) synthetic analog that is considered among compounds affecting GH/IGF-1 signaling pathways, and it also appears in research focused on doping detection and analytical stability/detection methods. (PMIDs: 41490200, 41966639, 34665524, 32257855, 37806509, 36787346)
Research literature describes tesamorelin as a growth hormone–releasing factor (growth hormone-releasing hormone) analogue that is FDA-approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy, with clinical studies reporting effects on visceral fat and related body-composition outcomes in that indication. Orthopaedic/sports-medicine reviews note a lack of supporting orthopaedic evidence for tesamorelin and identify broader gaps in clinical evidence for “injectable peptide therapy” in musculoskeletal contexts.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Family | GHRH analogs | GHRH analogs |
| Research goals | GH axis support | Metabolic & weight, GH axis support |
| Amino acids | — | — |
| Molecular formula | C149H246N44O42S | C221H366N72O67S |
| Molecular weight | 3357.9 g/mol | 5136 g/mol |
| CAS number | 86168-78-7 | 218949-48-5 |
| Approx. half-life | — | — |
| Regulatory status | Withdrawn | FDA-approved drug |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 9 | 10 |
| Vendors independently tested | 7 | 60 |
| Best test score (Finnrick) | 7.9 | 9.0 |